News

MSCA Radiance Cofund handbook 2026 and policy briefs ERA Policy Agenda, EU Missions and Green Transition published

Published on | 2 months ago

Programmes
MSCA

The Marie Sklodowska-Curie Actions (MSCA) Radiance NCP network has updated and published support material which is available for National Contact Points (NCPs) and applicants:

  • The RADIANCE COFUND Handbook and Submission Guide 2026 are valuable resources for proposal writing and submission preparation. The material is available here.
  • A new policy brief on the ERA Policy Agenda and updated policy briefs on EU Missions and the Green Transition are available here. These briefs offer a concise and practical overview of relevant EU policies. They help to understand different instruments and policy objectives of the European Union and their relations to the MSCA and can be of help when integrating key strategies into MSCA proposals.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1861 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.